Background: One challenge in clinical management of cutaneous melanoma (CM) is the limited predictability of recurrence and hence the progression to advanced stages that associate with less favorable outcomes. Aggressive follow-up care and novel adjuvant therapy strategies in early-stage patients with high-risk of recurrence would likely improve CM-specific survival and reduce mortality. We developed a genome-wide approach to identify germline genetic determinants of melanoma prognosis as putative personalized biomarkers for patients at risk of CM recurrence. Methods: Exploring both the coding and non-coding transcribed genome we performed germline whole genome sequencing (WGS) and tumor RNA-seq on 96 CM patients with tumor/blood matched specimens. All patients were of primary stages I-IIB and of Ashkenazi Jewish ancestry to reduce genetic heterogeneity. We compared 48 patients that recurred in < 4 years versus 48 patients with recurrence in > 6 years. Univariate and multivariate logistic regression, gene-burden analysis (SKAT), and differential expression analyses of both mRNA and lncRNAs were used to identify germline regions associated with melanoma recurrence. Results: Several gene regions were associated with melanoma recurrence, with NEGR1 and MGST3 both passing SKAT levels of significance (p < 1e-05), and logistic regression analysis on common WGS variants found over 100 variants with significance p < 1e-03. In addition, we found 200 differentially expressed putative lncRNAs (p < 0.05). The analysis of germline WGS found rs199818927, a 1bp insertion previously associated with both NEGR1 and lncRNA LINC01360, among our top 5 most significant regression results (OR ¼ 9.107 p ¼ 2.31e-05).
Background: The outcome of high risk stage III melanoma patients (pts) is poor, with a 5-year overall survival (OS) rate of < 50%. Adjuvant (adj) high dose IPI , adj NIVO and pembrolizumab improved RFS. Neo-adjuvant (neoadj) treatment may be an even more favorable approach as immune checkpoint inhibition is of greatest value at the moment of TCR triggering and therefore dependent on the amount of antigen present. In our previous phase Ib OpACIN study the pathological RR (pRR) was 78% in the neoadj arm, and to date after 25 months of median follow-up none of the responders has relapsed. This raises the question whether such pts need to undergo complete lymph node dissection (CLND). A prerequisite for such an approach would be an analysis method that reliably indicates pathological response within the whole lymph node bed, without the need for CLND. Methods: To address this question an in-house developed magnetic marker was placed ultrasound-guided at baseline into the largest regional lymph node metastasis of pts participating in OpACIN-neo, (NCT02977052), a phase 2 trial aiming at identification of the optimal neoadj combination scheme of IPI and NIVO in stage IIIB/C melanoma pts followed by CLND. Results: So far, 11 pts participated in this side trial of OpACIN-neo. No complications from marker placing were observed, and all magnetic markers were retrieved during the CLND after 6 weeks of neoadj IPIþNIVO. 10/11 marked lymph-nodes (LN were representative in their response for the whole CLND specimen, i.e. index node showed a complete or partial response (PR), all others on CLND showed the same or better responses. Only 1 case was incongruent, as the index LN had 60% vital tumor (no response) compared to another LN (40% vital tumor, PR 
